Skip to content

Author

F. Facchinetti

We have 2 of 154 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review

the MET gene for the treatment of non-small-cell

This review will focus on the MET pathway and its role in resistance to EGFR TK (tyrosine kinase) inhibitors, the different strategies of its inhibition, and the potential approaches to overcoming acquired resistance.

F. Gelsomino, F. Facchinetti, E. Haspinger et al. · 0 citations
Aug 2026

Therapeutic targeting of RAS-mediated resistance in oncogene-driven lung cancer.

RAS alterations mediate resistance to targeted agents in approximately 10% of oncogene-driven lung cancer, and Rational combinations with novel RAS inhibitors are effective in preclinical models, providing the basis for their clinical investigation and extending the paradigm of precision oncology.

F. Facchinetti, L. Friboulet, L. Liao et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.